Tech Company Financing Transactions
Eyevensys Funding Round
Eyevensys closed a $30 million Series B venture capital round on 1/9/2020. Investors included Boehringer Ingelheim Venture Fund, BB Pureos Bioventures and Bpifrance.
Transaction Overview
Company Name
Announced On
1/9/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic non-infectious uveitis (NIU), including the launch of its Electro Study, and advance the preclinical development of its other therapeutic proteins targeting ophthalmic diseases with unaddressed medical needs such as retinitis pigmentosa and age-related macular degeneration (AMD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11 rue Watt -- Bat B
Paris, 75013
France
Paris, 75013
France
Phone
Website
Email Address
Overview
Eyevensys is dedicated to the research and development of innovative therapies for the treatment of ocular diseases by non viral gene therapy. Eyevensys S.A.S. is a privately held biotechnology company developing a game changing approach to express therapeutic proteins in situ for the treatment of major ophthalmic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patricia Zilliox
Chief Medical Officer
Ronald Buggage
Chief Scientific Officer
Francine Behar-Cohen
Browse more venture capital transactions:
Prev: 1/9/2020: Indigo Ag venture capital transaction
Next: 1/9/2020: Aegle Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. All VC database entries on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs